Metabolic control of vascular smooth muscle cell plasticity
血管平滑肌细胞可塑性的代谢控制
基本信息
- 批准号:10334766
- 负责人:
- 金额:$ 63.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-01 至 2025-11-30
- 项目状态:未结题
- 来源:
- 关键词:Amino AcidsBindingBioinformaticsBlood VesselsBypassCarotid ArteriesChIP-seqCuesCyclin-Dependent KinasesDNADataDevelopmentDiseaseExhibitsFailureGenetic TranscriptionGlassGlucoseHyperplasiaIn VitroInvestigationKnockout MiceLesionLigationLightLinkLoxP-flanked alleleMapsMediatingMediator of activation proteinMetabolicMetabolic ControlMetabolismMolecularMusMuscle CellsOperative Surgical ProceduresOutcomePathogenesisPathway interactionsPhenotypePilot ProjectsProcessProtein GeranylgeranylationProto-Oncogene Proteins c-aktRegulatory ElementRoleSchemeSignal PathwaySignal TransductionSmooth Muscle MyocytesSterolsTestingVascular DiseasesVascular Smooth MuscleVascular remodelingVein graftaerobic glycolysisbeta Actincell dedifferentiationclinically relevantcombateffective therapyfatty acid oxidationin vivoinhibitorinnovationinsightmevalonatemouse modelnoveloverexpressionoxidationprotein metabolismsmall molecule inhibitortargeted treatmenttherapeutically effectivetranscriptome sequencing
项目摘要
The dedifferentiation of vascular smooth muscle cells (SMCs) into synthetic SMCs, a hallmark of many
occlusive vascular diseases, is associated with a metabolic switch that is characterized by increased aerobic
glycolysis, which also fuels mevalonate metabolism, decreased glucose oxidation and increased fatty acid
oxidation. However, the molecular links between environmental cues and the metabolic reprogramming remain
poorly understood. Our pilot studies revealed that cyclin dependent kinase 8 (CDK8) is a master regulator of
the metabolic control of vascular SMC dedifferentiation for intimal hyperplasia toward vascular occlusion.
Mechanistic investigations uncovered that CDK8 controls the SREBP2 (sterol regulatory element binding
factor-2)-operated transcription to promote the mevalonate metabolism for protein geranylgeranylation, which
drives the vascular SMC dedifferentiation. Thus, we propose a novel paradigm in which CDK8 controls the
mevalonate metabolism for protein geranylgeranylation to promote the dedifferentiation of vascular SMCs for
intimal hyperplasia, thereby contributing to occlusive vascular disease. We will test this hypothesis and
delineate the molecular mechanisms of CDK8-operated metabolic control of vascular SMC dedifferentiation by
2 specific aims: Aim 1 will establish a mediator role of CDK8 in vascular SMC dedifferentiation into synthetic
SMCs for intimal hyperplasia toward vascular occlusion; Aim 2 will determine the underlying molecular
mechanisms with a focus on the molecular network by which CDK8 operates the mevalonate metabolism
pathway for protein geranylgeranylation which is required for vascular SMC dedifferentiation into synthetic
SMCs leading to intimal hyperplasia toward vascular occlusion. This proposal will provide the first assessment
of CDK8-mediated occlusive vascular lesion formation and define a novel pathway of occlusive vascular
remodeling that is mediated by previously unrecognized CDK8-operated metabolic reprogramming for vascular
SMC dedifferentiation, thus shedding light on the study of vascular SMC plasticity as well as the development
of innovative and effective therapeutic approaches for occlusive vascular disease.
血管平滑肌细胞(SMC)去分化为合成SMC,这是许多平滑肌细胞的标志。
闭塞性血管疾病,与代谢开关,其特征是增加有氧
糖酵解也促进甲羟戊酸代谢,降低葡萄糖氧化,增加脂肪酸
氧化然而,环境因素和代谢重编程之间的分子联系仍然存在
不太了解。我们的初步研究表明,细胞周期蛋白依赖性激酶8(CDK 8)是一个主要的调节因子,
血管平滑肌细胞去分化的代谢控制内膜增生血管闭塞。
机制研究发现,CDK 8控制SREBP 2(固醇调节元件结合
因子-2)操纵的转录,以促进蛋白质香叶基香叶基化的甲羟戊酸代谢,
驱动血管SMC去分化。因此,我们提出了一种新的范式,其中CDK 8控制着细胞周期。
甲羟戊酸代谢的蛋白质香叶基香叶基化,促进血管平滑肌细胞的去分化,
内膜增生,从而导致闭塞性血管疾病。我们将测试这个假设,
描述CDK 8操作的血管SMC去分化代谢控制的分子机制,
2个具体目标:目标1将建立CDK 8在血管SMC去分化为合成的SMC中的介导作用。
平滑肌细胞内膜增生向血管闭塞;目标2将确定潜在的分子
机制,重点是CDK 8操作甲羟戊酸代谢的分子网络
蛋白质香叶基香叶基化的途径,这是血管SMC去分化为合成
SMC导致内膜增生,进而导致血管闭塞。这份提案将提供第一次评估,
CDK 8介导的闭塞性血管病变的形成,并定义了一种新的闭塞性血管病变的途径。
由先前未被识别的CDK 8操作的代谢重编程介导的血管重构
从而为血管平滑肌细胞可塑性的研究以及血管平滑肌细胞的发育提供了新的思路。
闭塞性血管疾病的创新和有效的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Taixing Cui其他文献
Taixing Cui的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Taixing Cui', 18)}}的其他基金
Cyclin-dependent kinase (CDK)19-mediated vein graft intimal hyperplasia
细胞周期蛋白依赖性激酶(CDK)19介导的静脉移植内膜增生
- 批准号:
10664327 - 财政年份:2023
- 资助金额:
$ 63.62万 - 项目类别:
Metabolic control of vascular smooth muscle cell plasticity
血管平滑肌细胞可塑性的代谢控制
- 批准号:
10829610 - 财政年份:2021
- 资助金额:
$ 63.62万 - 项目类别:
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure
探索 UCH-L1 作为心力衰竭新治疗和诊断靶点的潜力
- 批准号:
10709559 - 财政年份:2020
- 资助金额:
$ 63.62万 - 项目类别:
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure
探索 UCH-L1 作为心力衰竭新治疗和诊断靶点的潜力
- 批准号:
10467982 - 财政年份:2020
- 资助金额:
$ 63.62万 - 项目类别:
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure
探索 UCH-L1 作为心力衰竭新治疗和诊断靶点的潜力
- 批准号:
10011124 - 财政年份:2020
- 资助金额:
$ 63.62万 - 项目类别:
To explore the potential of UCH-L1 as a novel therapeutic and diagnostic target in heart failure
探索 UCH-L1 作为心力衰竭新治疗和诊断靶点的潜力
- 批准号:
10490344 - 财政年份:2020
- 资助金额:
$ 63.62万 - 项目类别:
The NRF2-p62 Axis in the Cross-Talk between Proteasomal and Lysosomal Degradation
蛋白酶体和溶酶体降解之间相互作用的 NRF2-p62 轴
- 批准号:
9311709 - 财政年份:2017
- 资助金额:
$ 63.62万 - 项目类别:
The NRF2-p62 Axis in the Cross-Talk between Proteasomal and Lysosomal Degradation
蛋白酶体和溶酶体降解之间相互作用的 NRF2-p62 轴
- 批准号:
9891075 - 财政年份:2017
- 资助金额:
$ 63.62万 - 项目类别:
A novel approach for transforming decelluarized vessel grafts into small-diameter arteries
将脱细胞血管移植物转化为小直径动脉的新方法
- 批准号:
9317769 - 财政年份:2017
- 资助金额:
$ 63.62万 - 项目类别:
UBIQUITIN CARBOXYL TERMINAL HYDROLASE L1 (UCH-L1) AND VASCULAR LESION FORMATION
泛素羧基末端水解酶 L1 (UCH-L1) 与血管病变形成
- 批准号:
8167799 - 财政年份:2010
- 资助金额:
$ 63.62万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321481 - 财政年份:2024
- 资助金额:
$ 63.62万 - 项目类别:
Continuing Grant
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321480 - 财政年份:2024
- 资助金额:
$ 63.62万 - 项目类别:
Continuing Grant
Alkane transformations through binding to metals
通过与金属结合进行烷烃转化
- 批准号:
DP240103289 - 财政年份:2024
- 资助金额:
$ 63.62万 - 项目类别:
Discovery Projects
NPBactID - Differential binding of peptoid functionalized nanoparticles to bacteria for identifying specific strains
NPBactID - 类肽功能化纳米粒子与细菌的差异结合,用于识别特定菌株
- 批准号:
EP/Y029542/1 - 财政年份:2024
- 资助金额:
$ 63.62万 - 项目类别:
Fellowship
Conformations of musk odorants and their binding to human musk receptors
麝香气味剂的构象及其与人类麝香受体的结合
- 批准号:
EP/X039420/1 - 财政年份:2024
- 资助金额:
$ 63.62万 - 项目类别:
Research Grant
Postdoctoral Fellowship: OPP-PRF: Understanding the Role of Specific Iron-binding Organic Ligands in Governing Iron Biogeochemistry in the Southern Ocean
博士后奖学金:OPP-PRF:了解特定铁结合有机配体在控制南大洋铁生物地球化学中的作用
- 批准号:
2317664 - 财政年份:2024
- 资助金额:
$ 63.62万 - 项目类别:
Standard Grant
I-Corps: Translation Potential of Real-time, Ultrasensitive Electrical Transduction of Biological Binding Events for Pathogen and Disease Detection
I-Corps:生物结合事件的实时、超灵敏电转导在病原体和疾病检测中的转化潜力
- 批准号:
2419915 - 财政年份:2024
- 资助金额:
$ 63.62万 - 项目类别:
Standard Grant
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 63.62万 - 项目类别:
Research Grant
CRII: OAC: Development of a modular framework for the modeling of peptide and protein binding to membranes
CRII:OAC:开发用于模拟肽和蛋白质与膜结合的模块化框架
- 批准号:
2347997 - 财政年份:2024
- 资助金额:
$ 63.62万 - 项目类别:
Standard Grant
How lipid binding proteins shape the activity of nuclear hormone receptors
脂质结合蛋白如何影响核激素受体的活性
- 批准号:
DP240103141 - 财政年份:2024
- 资助金额:
$ 63.62万 - 项目类别:
Discovery Projects